Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Lel H who wrote (119)	8/16/1998 4:15:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 626

Hi Lel. I was in Europe for several weeks, so sorry for late respond. Yahoo boards have loot of junk posts, so I am not visiting very often. Regards the TTNP board, InvestorMD is puzzling me because he change sentiment to often. Streets concern on iloperidone development is growing, and is reflecting stock price. I do not see any trouble in the iloperidone development and Novartis involvement. Abbott and Pfizer failure with new antipsyhotic drugs show that FDA did rise expectation and requirement for approval of new drugs. The point is that Novartis (imo iloperidone is important drug for them) will not rush with PIII trials to satisfy TTNP or its SH. My understanding is that this should be multiple arms (three drugs: iloperidone, haloperidol and risperidon) double blind placebo controlled randomized trials, so Novartis have to prepare equal pills for all three drugs (with two iloperidone dose) to satisfy blind requirements. If it is not double blind trials than blind requirements are for two iloperidone dose and placebo pills. This is not a technical problems, but it is time-consuming. Just my opinion for small trial delay. Take care. Miljenko